# Adiponectin gene SNP $276G \rightarrow T$ , nutrient intakes, and cardiovascular disease risk in Korean type 2 DM patients<sup>\*</sup>

So Young Yu<sup>1</sup>, Han Kyoung Ryu<sup>1</sup>, Hee Jung Park<sup>2</sup>, Young Ju Choi<sup>3</sup>, Kap Bum Huh<sup>3</sup> and Wha Young Kim<sup>1§</sup> <sup>1</sup>Department of Nutritional Science and Food Management, Ewha Womans University <sup>2</sup>CJ Corp. Foods R&D, Seoul 152-050, Korea

<sup>3</sup>21C Diabetics and Vascular Research Center, Seoul 121-806, Korea

Received November 20, 2007; Revised December 6, 2007; Accepted December 12, 2007

#### Abstract

Single nucleotide polymorphism (SNP) in adiponectin gene has been associated with insulin resistance, diabetes, and cardiovascular disease (CVD). This study was performed to investigate the association of SNP 276G $\rightarrow$ T at adiponectin gene with CVD risk factors in Korean type 2 diabetes mellitus (DM) patients. The subjects were 351 type 2 DM patients visited a DM clinic in Seoul, and the patients with known CVD were excluded. The adiponectin SNP 276G $\rightarrow$ T was analyzed and dietary intakes were assessed by a Food Frequency Questionnaire. The prevalence of G/G, G/T, and T/T genotype was 47.6%, 43.3%, and 9.1%, respectively. Male subjects with T/T genotype showed significantly lower level of adiponectin and HDL-cholesterol and significantly higher C-reactive protein (CRP) level compared to G/G and G/T genotypes. In G/G genotype, protein intake was negatively correlated to body weight, BMI, and waist circumference, and there were positive correlation between carbohydrate intake and BMI, waist-hip ratio, and ApoB/apoA-1 ratio in G/T genotype. However, in T/T genotype, there was no significant association between macronutrient intakes and anthropometric and hematological values. In conclusion, CVD risk would be high in type 2 DM patients with T/T genotype, and the association of macronutrient intakes with anthropometric and hematologic factors was different among the three adiponectin genotypes. These results may imply the need for different dietary management regime according to adiponectin genotype to lower CVD complications in Korean type 2 DM patients.

Key Words: Adiponectin SNP 276G→T, adiponectin, insulin resistance, type 2 diabetes, cardiovascular disease risk factors

#### Introduction

Adiponectin is the most abundant adipocyte-secreted hormone in blood, and it has been thought to be associated with insulin resistance (Kadosaki *et al.*, 2006). Plasma adiponectin levels have been reported to be reduced in patients with obesity (Arita *et al.*, 1999), type 2 diabetes (Hotta *et al.*, 2000), and coronary vascular diseases (CVD) (Hotta *et al.*, 2000), all of which are closely related to insulin resistance. Adiponectin also regulates inflammatory response and has an antiatherogenic effect (Ouchi *et al.*, 2003). A linkage has been reported between the single nucleotide polymorphism (SNP) in adiponectin gene and serum adiponectin level and CVD risk factors (Jang *et al.*, 2005; Qi *et al.*, 2006).

Adiponectin gene consists of 3 exons and 2 introns and is located on chromosome 3q27 (Bionnet *et al.*, 2000). Many of SNPs at adiponectin gene have been shown to be related to insulin resistance, type 2 diabetes, and CVD. Among those, adiponectin SNP 45T $\rightarrow$ G in exon 2 and SNP 276G $\rightarrow$ T in intron

2 were shown to be associated with type 2 diabetes in a Japanese population (Hara *et al.*, 2002), and the SNP  $276G \rightarrow T$  was observed to have a strong association with CVD risk in white diabetic patients (Bacci *et al.*, 2004) and in non-diabetic Koreans (Jang *et al.*, 2005).

Dietary factors play an important role in the development of type 2 diabetes and CVD. In addition, the expression of gene could be modified by environmental factors including diet, and the genetic variation may have effect on metabolic response to diet (Mutch *et al.*, 2005; Ordovas, 2006). Although the concept of personalized nutritional management according to genotype was introduced years ago, this time it is early stage of personalized nutrition and much more researches have to be performed for the scientific evidence.

The primary goal of this study was to investigate the association of SNP 276G $\rightarrow$ T at adiponectin gene with CVD risk factors in Korean type 2 diabetes mellitus (DM) patients. We also examined the association between adiponectin SNP 276G $\rightarrow$ T and dietary intakes.

<sup>\*</sup> This work was supported by Seoul R&BD Program, No. 10526 and by the second stage of BK21 Project in 2007

<sup>&</sup>lt;sup>§</sup> Corresponding Author: Wha-Young Kim, Tel. 82-2-3277-3093, Fax. 82-2-3277-2862, Email. wykim@ewha.ac.kr

# Subjects and Methods

#### Subjects

The subjects of this study were 351 type 2 DM patients aged over 20 years (191 males, 160 females) visited DM clinic in Seoul from October 2005 to August 2006. At the first visit, blood was drawn after a minimum of 12h fasting, and anthropometric parameters and dietary intake were also measured. After the examination, only the patients diagnosed as type 2 DM were included in this study, and the patients with known CVD (myocardial infarction, angina, stroke, and aortic disease) were excluded. Written informed consent was obtained from all subjects. The protocol was approved by the Institutional Review Board of Yonsei University.

#### Dietary, anthropometric, and hematological assessment

Information on food consumption, general characteristics, and life-style behavior were obtained by a self-administered questionnaire. Food consumption was assessed using a food frequency questionnaire (Oh *et al.*, 2007). Food intake data were analyzed using the Can-pro 3.0 software (Korean Nutrition Society, Korea) for nutrient analysis to determine nutrient intakes. For anthropometric measurements, body weight, height, and body composition were assessed using INBODY 4.0 (Biospace Co. Korea). Waist circumferences were measured by a tapeline, and abdominal fat thickness was assessed by ultrasonographic measurement (General Electric logic 7. USA). Body mass index (BMI, kg/m<sup>2</sup>) was calculated.

Fasting blood samples were obtained in EDTA-containing tubes in the morning and were frozen at -80 °C in aliquots. Fasting blood glucose level was measured by Accutrend alpha (Boehringer Mannhin Gmbh, Germany), and hemoglobin A1c level was determined using HLC-823 G7 (Tosoh, Japan). Plasma levels of total cholesterol, triglyceride and HDL-cholesterol were measured using an automatic blood analyzer (COBAS MIRA, Switzerland). LDL-cholesterol level was calculated by the formula of Friedwald (Friedwald *et al.*, 1972). Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-6 (IL-6), adiponectin (R&D Systems Inc., USA), and leptin (BioVendor Lab. Med., Czech Republic) were measured by ELISA Kit. The plasma glucose disappearance rate after intravenous injection of regular insulin (0.1 U'kg) was determined, and this result of Insulin Tolerance Test (K<sub>ITT</sub> (%/min)) was used as index of insulin resistance.

## Genotyping

Genomic DNA was extracted from heparinized venous blood samples using the QIAamp DNA blood mini kit (Quiagen Ltd, Crawley, UK). Identification of the polymorphism was carried out using PCR (GeneAmp PCR system 9700, Applied Biosystems, USA), followed by a restriction fragment length polymorphism (RFLP) assay. The promoter region of the adiponectin gene was amplified by polymerase chain-reaction (PCR) using the forward primer 5'-GGC CTC TTT CAT CAC AGA CC-3' and the reverse primer 5'-AGA TGC AGC AAA GCC AAA GT-3'. The PCR products were digested with BsmI (New England BioLabs), and the digestion products were resolved by electrophoresis in a 3% agarose gel.

#### Statistical analysis

Statistical analysis was conducted using the statistical analysis system program (SAS, version 9.1). Data were expressed as the mean±standard error. General characteristics and lifestyle behavior were compared by the chi-square test. After the subjects were classified into three groups according to SNP 276G $\rightarrow$ T at adiponectin gene, General Linear Model and Duncan's multiple range test were used to analyze between-group differences of the mean for all measured parameters. To test the difference between two groups, Student's t-test was used. Pearson's partial correlation coefficient analysis was used to test the association between nutrient intake and CVD risk factors according to adiponectin genotype. The levels of CRP, TNF- $\alpha$ , IL-6, leptin, and adiponectin were transformed to natural log for Duncan's multiple range test and correlation coefficient analysis because they were not normally distributed.

#### Results

# Genetic distribution of adiponectin 276 G/T and general characteristics of the subjects

A PCR-based BsmI-RFLP analysis was developed as a rapid screening method (Figure 1). One hundred sixty seven (47.6%) were homozygous for the wild-type allel (G/G), 152 (43.3%) were heterozygous (G/T) and only 32 (9.1%) were homozygous for the mutation (T/T). The mean age of male and female subjects was 54.1 and 58.1 years, and the mean DM duration was 7.23 years and 8.94 years, respectively. No significant differences in age and DM duration among three genotypes were found (Table 1). Subjects with DM family history were 92 (48.9%) in male and 70 (45.2%) in female subjects. About 70.7% of the subjects exercised regularly. The proportion of cigarette smokers and




Fig. 1. PCR-based Bsm-RFLP analysis of the intron-2 polymorphism of the adiponectin gene

Table 1. General characteristics of the subjects according to adiponectin SNP 276G→T

		Ma	ale		Female				
	All (n=191)	G/G (n=98)	G/T (n=75)	T/T (n=18)	All (n=160)	G/G (n=69)	G/T (n=77)	T/T (n=14)	
Ages	54.1±0.74 <sup>1)</sup>	53.4±1.09 <sup>ns3)</sup>	55.8±1.04	51.2±2.54	58.1±0.73	58.3±1.18 <sup>ns</sup>	58.6±0.97	55.0±2.67	
Duration of DM	7.23±0.56	6.83±0.82 <sup>ns</sup>	7.29±0.78	9.31±2.63	8.94±0.61	9.24±0.77 <sup>ns</sup>	8.63±0.96	9.19±2.97	
Family history Yes No	92(48.9) <sup>2)</sup> 96(51.1)	50(51.5) <sup>NS4)</sup> 47(48.5)	34(45.9) 40(54.1)	8(47.1) 9(52.9)	70(45.2) 85(54.8)	31(46.3) <sup>NS</sup> 36(53.7)	30(40.5) 44(59.5)	9(64.3) 5(35.7)	
Cigarette smoking Non-smoker Ex-smoker Current-smoker	39(23.4) 82(49.1) 46(27.5)	16(19.3) <sup>NS</sup> 45(54.2) 22(26.5)	21(30.4) 28(40.6) 20(29.0)	2(13.3) 9(60.0) 4(26.7)	129(93.5) 6(4.3) 3(2.2)	59(98.3) <sup>NS</sup> 1(1.7) 0(0.0)	62(91.2) 4(5.9) 2(2.9)	8(80.0) 1(10.0) 1(10.0)	
Alcohol drinking Non-drinker Ex-drinker Current-drinker	32(19.1) 32(19.0) 104(61.9)	14(16.9) <sup>NS</sup> 15(18.1) 54(65.0)	15(21.4) 14(20.0) 41(58.6)	3(20.0) 3(20.0) 9(60.0)	35(24.8) 81(57.5) 25(17.7)	19(30.7) <sup>NS</sup> 33(53.2) 10(16.1)	14(20.3) 40(58.0) 15(21.7)	2(20.0) 8(80.0) 0(0.0)	
Exercise Yes No	119(71.7) 47(28.3)	54(65.9) <sup>NS</sup> 28(34.1)	51(73.9) 18(26.1)	14(93.3) 1(6.67)	99(70.2) 42(29.8)	42(67.7) <sup>NS</sup> 20(36.3)	50(72.5) 19(27.5)	7(70.0) 3(30.0)	
Medication usage, Yes/No (%) Diabetes Hypertension Dyslipidemia	66.5/33.5 21.5/78.5 16.7/83.3	62.2/37.8 <sup>NS</sup> 16.3/83.7 <sup>NS</sup> 13.3/86.7 <sup>NS</sup>	76.0/24.0 28.0/72.0 20.0/80.0	50.0/50.0 22.2/77.8 22.2/77.8	76.3/23.7 25.6/74.4 18.1/81.9	78.3/21.7 <sup>NS</sup> 30.4/69.6 <sup>NS</sup> 20.3/79.7 <sup>NS</sup>	74.0/26.0 23.4/76.6 15.6/84.4	78.6/21.4 14.3/85.7 21.4/78.6	

Mean±SE

<sup>2)</sup> n (%)

 $^{31}$  ns: not significant among the three genotypes in the same gender by Duncan's multiple range test; p<0.05

<sup>4)</sup> NS: not significant among the three genotypes in the same gender by Chi-square test; p < 0.05

alcohol drinkers were 27.5% and 61.9% of the male subjects, 2.2% and 17.7% of the female subjects, respectively. There were no significant differences in drinking, smoking, and exercising habits among three groups in both genders. Medication usages for diabetes, hypertension, and dyslipidemia were not significantly different.

#### Anthropometric variables according to adiponectin genotype

As shown in Table 2, mean heights/weights of male and female subjects were 168.2 cm/69.7 kg and 156.4 cm/59.4 kg, respectively. For male and female subjects, BMI values were 24.6 kg/m<sup>2</sup> and 24.3 kg/m<sup>2</sup>, waist circumferences were 85.2 cm and 79.7 cm, body fat mass were 16.2 kg and 18.7 kg, percentages of body fat were 22.6% and 30.5%, and abdominal fat thickness were 48.4 mm and 43.7 mm, respectively. In all the measured

anthropometric variables, significant differences were not found among adiponectin genotype groups in both male and female subjects.

## Hematological variables according to adiponectin genotype

Hematological values of the subjects are shown in Table 3. Plasma concentrations of insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, leptin and adiponectin were significantly higher in females than in males (p < 0.05), however, no differences were found in insulin resistance (K<sub>ITT</sub>), fasting blood glucose, hemoglobin A1c, triglyceride, apoB/apoA-1 ratio, CRP, TNF-a and IL-6 levels between male and female subjects.

In male subjects, mean values of KITT, fasting blood glucose, hemoglobin A1c, and insulin, total cholesterol, LDL-cholesterol, and triglyceride were not significantly different among three

Table 2. Anthropometric variables of the subjects according to adiponectin SNP 276G→T

	Male				Female				
	All (n=191)	G/G (n=98)	G/T (n=75)	T/T (n=18)	All (n=160)	G/G (n=69)	G/T (n=77)	T/T (n=14)	
Weight(kg)	69.7 ± 0.76 <sup>1)</sup>	68.9 ± 1.09	70.9 ± 1.21	68.7 ± 2.21	59.4 ± 0.74	60.1 ± 1.07	58.4 ± 1.07	61.0 ± 2.96	
BMI(kg/m <sup>2</sup> ) <sup>2)</sup>	24.6 ± 0.21	24.3 ± 0.29	$24.9 \pm 0.33$	$24.4 \pm 0.73$	24.3 ± 0.28	$24.6 \pm 0.43$	$23.9 \pm 0.38$	24.7 ± 1.17	
Waist (cm)	85.2 ± 0.62	84.2 ± 0.89	86.3 ± 1.01	85.8 ± 1.48	79.7 ± 0.67	80.1 ± 0.96	79.5 ± 0.97	79.4 ± 2.98	
WHR <sup>3)</sup>	$0.910 \pm 0.00$	$0.905 \pm 0.00$	$0.918 \pm 0.01$	$0.908 \pm 0.01$	0.911 ± 0.00	$0.918 \pm 0.01$	0.907 ± 0.01	$0.898 \pm 0.02$	
Fatmass(kg)	16.2 ± 0.37	15.9 ± 0.51	17.1 ± 0.61	15.1 ± 0.94	18.7 ± 0.46	19.4 ± 0.71	18.2 ± 0.64	18.7 ± 1.89	
Body fat(%)	22.6 ± 0.36	$22.5 \pm 0.47$	$22.8 \pm 0.64$	22.3 ± 1.08	30.5 ± 0.47	31.0 ± 0.73	$30.2 \pm 0.65$	29.6 ± 1.69	
AFT(mm) <sup>4)</sup>	48.4 ± 1.40	46.1 ± 1.96	50.6 ± 2.38	52.3 ± 2.88	43.7 ± 1.49	43.5 ± 2.19	43.5 ± 2.17	46.0 ± 5.75	

<sup>1)</sup> Mean±SE

<sup>2)</sup> BMI: Body mass index

3) WHR: Waist/hip circumferences ratio

4) AFT: Abdominal fat thickness

# Adiponectin gene SNP 276G→T and CVD risk

Table 3. Hematologi	al variables of the subjects according to adiponectin SNP 276G $ ightarrow$ T	

	Male				Female					
	All (n=191)	G/G (n=98)	G/T (n=75)	T/T (n=18)	All (n=160)	G/G (n=69)	G/T (n=77)	T/T (n=14)		
K <sub>ITT (</sub> %/min) <sup>1)</sup>	$2.10 \pm 0.08^{2)}$	2.14 ± 0.11	2.03 ± 0.12	2.21 ± 0.25	2.18 ± 0.08	2.09 ± 0.12	2.25 ± 0.13	2.21 ± 0.18		
FBS(mg/dl)3)	162.9 ± 4.19	166.2 ± 6.19	157.2 ± 6.06	169.7 ± 14.7	166.1 ± 4.72	152.7 ± 6.26	$176.5 \pm 6.80$	174.4 ± 22.2		
HbA1c(%) <sup>4)</sup>	8.32 ± 0.16	8.42 ± 0.26	8.20 ± 0.22	8.22 ± 0.35	8.53 ± 0.15	$8.23 \pm 0.23^{b5)}$	$8.62 \pm 0.20^{b}$	$9.51 \pm 0.67^{a}$		
Insulin(ng/dl)	$7.79 \pm 0.29^{*6)}$	7.62 ± 0.43	$7.86 \pm 0.39$	8.44 ± 0.92	$8.78 \pm 0.35$	8.85 ± 0.57	$8.54 \pm 0.48$	9.77 ± 1.11		
T-Chol (mg/dl)7)	182.6 ± 2.67*	186.0 ± 4.05	180.3 ± 3.88	174.1 ± 7.61	199.1 ± 3.23	198.6 ± 4.51	199.7 ± 4.87	198.5 ± 13.1		
LDL-Chol (mg/dl) <sup>8)</sup>	107.6 ± 2.37*	112.5 ± 3.44	103.5 ± 3.69	98.7 ± 6.11	117.9 ± 2.94	115.5 ± 4.25	$119.8 \pm 4.46$	119.9 ± 10.1		
HDL-Chol (mg/dl) <sup>9)</sup>	48.5 ± 1.05*	$49.0 \pm 1.45^{a}$	$49.4 \pm 1.69^{a}$	$42.0 \pm 3.18^{b}$	53.6 ± 7.21	54.0 ± 1.99	53.2 ± 1.67	53.6 ± 3.51		
TG (mg/dl) 10)	132.5 ± 5.47	127.5 ± 7.95	134.6 ± 7.86	151.7 ± 21.5	139.6 ± 7.16	133.2 ± 8.06	147.7 ± 12.5	126.5 ± 19.2		
ApoB/apoA-1 <sup>11)</sup>	$0.85 \pm 0.02$	0.85 ± 0.03	$0.83 \pm 0.04$	$0.92 \pm 0.06$	$0.85 \pm 0.03$	$0.83 \pm 0.04$	$0.87 \pm 0.04$	$0.84 \pm 0.09$		
CRP(mg/dl) <sup>12)</sup>	1.47 ± 0.16	1.19 ± 0.17 <sup>b</sup>	$1.63 \pm 0.28^{ab}$	$2.50 \pm 0.81^{a}$	$1.48 \pm 0.18$	1.26 ± 0.18	1.64 ± 0.30	$1.70 \pm 0.75$		
TNF-a(pg/ml) <sup>13)</sup>	$1.29 \pm 0.05$	$1.19 \pm 0.06$	$1.42 \pm 0.09$	$1.22 \pm 0.14$	$1.25 \pm 0.06$	$1.26 \pm 0.09$	$1.26 \pm 0.08$	$1.19 \pm 0.17$		
IL-6(pg/ml) <sup>14)</sup>	1.46 ± 0.13	1.17 ± 0.13	$1.84 \pm 0.25$	$1.46 \pm 0.51$	$1.19 \pm 0.10$	$1.04 \pm 0.11$	1.21 ± 0.13	$1.89 \pm 0.69$		
Leptin(ng/ml)	2.51 ± 0.22*	2.59 ± 0.34	$2.61 \pm 0.32$	$1.69 \pm 0.25$	$9.12 \pm 0.69$	9.87 ± 1.15	$8.25 \pm 0.90$	10.2 ± 2.51		
Adiponectin (µg/ml)	4.05 ± 0.36*	$4.21 \pm 0.49^{a}$	$4.20 \pm 0.60^{a}$	$2.53 \pm 0.63^{b}$	6.81 ± 0.50	6.64 ± 0.71	7.29 ± 0.79	4.96 ± 1.21		

<sup>1)</sup> K<sub>ITT</sub>(%/min): Insulin tolerance test index

<sup>2)</sup> Mean±SE

<sup>3)</sup> FBS: Fasting blood sugar

<sup>4)</sup> HbA1c: Hemoglobin A1c

<sup>5)</sup> Values with different alphabets are significantly different among the three genotypes in same gender by Duncan's multiple range test; p (0.05  $^{\circ}$  \*; significantly different between male and female subjects by student's t-test; p (0.05

7) T-Chol: Total cholesterol

<sup>8)</sup> LDL-Chol: LDL cholesterol

<sup>9)</sup> HDL-Chol: HDL cholesterol

<sup>10)</sup> TG: Triglyceride

<sup>11)</sup> Apolipoprotein B/apolipoprotein A-1 ratio

<sup>12)</sup> CRP: C-reactive protein <sup>13)</sup> TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ 

<sup>14)</sup> IL-6: Interleukin-6

#### Table 4. Hematological variables of the subjects according to $K_{ITT}$ index and adiponectin SNP 276G $\rightarrow$ T

		I	R		NIR					
	All (n=170)	G/G (n=81)	G/T (n=79)	T/T (n=10)	All (n=181)	G/G (n=86)	G/T (n=73)	T/T (n=22)		
K <sub>ITT (</sub> %/min) <sup>1)</sup>	$1.27 \pm 0.03^{2)^*}$	1.29 ± 0.05	1.24 ± 0.06	1.28 ± 0.16	2.96 ± 0.06	$2.91 \pm 0.09^{ab}$	$3.11 \pm 0.09^{a}$	$2.63 \pm 0.15^{b}$		
FBS(mg/dl) 3)	$184.7 \pm 4.93^{*^{4)}}$	182.9 ± 7.17	183.9 ± 6.94	204.8 ± 26.8	145.3 ± 3.37	139.6 ± 4.43	148.6 ± 5.25	156.7 ± 12.8		
HbA1c(%) <sup>5)</sup>	9.01 ± 0.17*	9.01 ± 0.29	9.01 ± 0.21	8.96 ± 0.81	7.84 ± 0.13	$7.69 \pm 0.19^{b}$	$7.76 \pm 0.19^{b}$	$8.73 \pm 0.41^{a}$		
Insulin(ng/dl)	8.91 ± 0.35*	9.06 ± 0.58	$8.69 \pm 0.43$	9.40 ± 1.09	$7.59 \pm 0.28$	$7.23 \pm 0.38$	$7.66 \pm 0.45$	8.87 ± 0.92		
T-Chol (mg/dl) <sup>6)</sup>	194.0 ± 3.24*	197.3 ± 4.35	$192.2 \pm 4.99$	183.3 ± 45.6	186.5 ± 2.73	185.6 ± 4.20	187.9±3.96	185.4 ± 8.27		
LDL-Chol (mg/dl) <sup>7)</sup>	113.3 ± 2.96	117.2 ± 4.04	110.8 ± 1.63	102.7 ± 11.2	111.3 ± 2.37	110.8 ± 3.52	$112.3 \pm 3.65$	110.4 ± 6.92		
HDL-Chol (mg/dl) <sup>8)</sup>	48.6 ± 1.21	48.7 ± 1.90 <sup>a9)</sup>	$49.9 \pm 1.63^{a}$	$38.0 \pm 3.67^{b}$	52.9 ± 1.04	53.4 ± 1.44	52.8 ± 1.75	51.2 ± 2.94		
TG (mg/dl) <sup>10)</sup>	161.5 ± 7.36	155.9 ± 9.25 <sup>b</sup>	160.5 ± 11.9 <sup>b</sup>	$214.7 \pm 32.3^{a}$	111.7 ± 4.42	105.9 ± 5.87	120.4 ± 8.10	$104.9 \pm 7.23$		
ApoB/apoA-1 <sup>11)</sup>	0.91 ± 0.03*	0.91 ± 0.04	$0.90 \pm 0.04$	$1.00 \pm 0.12$	$0.79 \pm 0.02$	$0.78 \pm 0.03$	$0.79 \pm 0.03$	$0.82 \pm 0.05$		
CRP(mg/dl) 12)	$1.68 \pm 0.19^{2}$	1.39 ± 0.23	$1.96 \pm 0.34$	1.88 ± 0.63	1.28 ± 0.13	$1.06 \pm 0.11$	$1.30 \pm 0.22$	2.36 ± 0.81		
TNF-a(pg/ml) <sup>13)</sup>	1.39 ± 0.06*	1.33 ± 0.09	$1.42 \pm 0.08$	1.67 ± 0.26	$1.16 \pm 0.05$	$1.12 \pm 0.06$	$1.25 \pm 0.10$	$0.99 \pm 0.07$		
IL-6(pg/ml) 14)	1.54 ± 0.14*	$1.13 \pm 0.12$	1.86 ± 0.23	2.11 ± 0.81	$1.17 \pm 0.10$	1.11 ± 0.13	$1.16 \pm 0.14$	$1.45 \pm 0.48$		
Leptin(ng/ml)	$5.69 \pm 0.56$	6.01 ± 0.84	$5.58 \pm 0.82$	3.97 ± 1.75	$5.36 \pm 0.52$	5.16 ± 0.81	$5.38 \pm 0.69$	6.08 ± 1.76		
Adiponectin (µg/ml)	$5.15 \pm 0.45$	$5.16 \pm 0.62^{a}$	$5.42 \pm 0.71^{a}$	$2.87 \pm 0.99^{b}$	$5.48 \pm 0.43$	$5.25 \pm 0.58^{ab}$	$6.17 \pm 0.76^{a}$	$3.98 \pm 0.88^{b}$		

 $\stackrel{\scriptscriptstyle (1)}{\scriptstyle \sim}$  K\_{ITI}(%/min): Insulin tolerance test index

<sup>2)</sup> Mean±SE

<sup>a</sup>) FBS: Fasting blood sugar <sup>a</sup>) \*; significantly different between male and female subjects by student's t-test; p(0.05)

<sup>5)</sup> HbA1c: Hemoglobin A1c <sup>6)</sup> T-Chol: Total cholesterol

7) LDL-Chol: LDL cholesterol

<sup>10)</sup> TG: Triglyceride

Apolipoprotein B/apolipoprotein A-1 ratio

<sup>12)</sup> CRP: C-reactive protein <sup>13)</sup> TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ <sup>14)</sup> IL-6: Interleukin-6

genotype groups. On the other hand, male subjects with T/T genotype showed significantly lower levels of HDL-cholesterol and adiponectin and higher CRP compared to other genotypes (p<0.05).

In female subjects, mean values of fasting blood glucose, and insulin, plasma lipids, and immune variables were not significantly different. However, hemoglobin A1c level was significantly higher in T/T genotype than other two genotypes (p<0.05).

# Hematological variables according to KITT value and adiponectin genotype

Since it has been suggested that insulin resistance has an important role in etiology of type 2 DM and CVD, the effect of adiponectin polymorphism on CVD risk factors could be confounded by insulin resistance. To explain the effect of insulin resistance, the subjects were divided into two groups based on  $K_{ITT}$  value, and the effect of adiponectin polymorphism on hematological variables were analyzed (Table 4); the subjects of  $K_{ITT}$  below 2%/min were grouped as Insulin Resistant group (IR), and the subjects of  $K_{ITT}$  over 2%/min were grouped as Non Insulin Resistant group (NIR). Because the subject number was limited, groups could not be subdivided according to gender.

Plasma concentrations of fasting blood glucose, hemoglobin A1c, insulin, triglyceride, apoB/apoA-1 ratio, TNF-a and IL-6 were significantly higher in IR group than in NIR group ( $p \le 0.05$ ),

and no differences were found in total cholesterol, LDL-cholesterol, CRP, leptin and adiponectin level between IR and NIR group.

In IR group, mean concentrations of adioponectin and HDLcholesterol were significantly lower, and triglyceride level was significantly higher in subjects with T/T genotype than the other two genotypes (p < 0.05). In NIR group, the subjects with T/T genotype showed significantly higher insulin resistance and hemoglobin A1c level and significantly lower adiponectin concentration than the subjects with other two genotypes

# Adiponectin concentration according to adiponectin genotype and CVD risk factors

To identify if the effect of adiponectin genotype on adiponectin concentration is shifted by other CVD risk factors, the subjects were divided into high and low subgroups based on the median values of BMI, fasting blood glucose, triglyceride, and TNF- $\alpha$ . Mean concentrations of adiponectin were compared according to the adiponectin genotype in each subgroup (Figure 2). In the high BMI, fasting blood glucose, triglyceride, and TNF- $\alpha$  subgroups, the subjects with T/T genotype showed significantly lower adiponectin concentration than other genotypes (p<0.05). However, in low subgroups, no significant differences were found in adiponectin concentration among three genotypes.




Fig. 2. Serum adiponectin concentration according to adiponectin genotype in the each subgroups of median of BMI, fasting blood sugar, triglyceride, and TNF-a

#### Adiponectin gene SNP 276G→T and CVD risk

Table 5. The Pearson's partial correlation coefficients between nutrient intakes and anthropometric and hematological factors according to adiponectin SNP 276G-T

		G/G (n=167)			G/T (n=152)			T/T (n=32)			
	Carbohy drate(g)	Protein(g)	Lipid(g)	Carbohy drate(g)	Protein(g)	Lipid(g)	Carbohy drate(g)	Protein(g)	Lipid(g)		
Weight(kg)	0.112	-0.293***	-0.092	0.085	-0.011	-0.069	-0.082	0.174	0.208		
BMI(kg/m <sup>2</sup> )	0.153	-0.276**	-0.096	0.196*	-0.106	-0.134	-0.106	-0.095	0.006		
Waist(cm)	0.118	-0.252**	-0.099	0.152	-0.086	-0.123	0.033	0.052	0.054		
WHR	0.121	-0.249**	-0.070	0.209*	-0.179	-0.148	0.157	-0.095	-0.132		
Fat mass(kg)	0.143	-0.289***	-0.085	0.147	-0.101	-0.104	0.028	0.174	-0.004		
FBS(mg/dl)	0.019	-0.050	-0.076	-0.095	0.021	0.035	0.133	-0.146	-0.178		
Insulin(ng/dl)	0.173*	-0.116	-0.147	0.128	-0.139	-0.207*	-0.232	0.279	0.246		
T-chol(mg/dl)	-0.024	0.007	0.007	0.191*	-0.146	-0.123	-0.157	0.131	0.114		
LDL-C(mg/dl)	0.021	0.009	0.013	0.253**	-0.169	-0.157	-0.114	0.109	0.078		
HDL-C(mg/dl)	-0.042	0.058	0.016	-0.259**	0.145	0.247**	-0.107	-0.039	0.144		
TG(mg/dl)	-0.100	-0.032	-0.003	0.103	-0.088	-0.155	-0.112	0.174	0.034		
ApoB/apoA-1	0.127	-0.093	-0.145	0.373***	-0.251**	-0.316***	-0.092	0.161	0.011		
CRP(mg/dl)	0.048	-0.149	-0.018	0.126	-0.257**	-0.147	0.151	-0.027	-0.219		
TNF-a(pg/ml)	0.107	-0.183*	-0.116	0.172	-0.207*	-0.119	-0.111	0.214	0.081		
IL-6(pg/ml)	0.021	-0.098	0.004	0.109	-0.163	-0.089	0.388	-0.289	-0.432		
Leptin(ng/ml)	0.210*	-0.214*	-0.201*	0.139	-0.183	-0.112	-0.393	0.463	0.256		
Adiponectin (µg/ml)	-0.135	0.106	0.171	-0.275**	0.212*	0.219*	-0.073	-0.039	0.062		

Adjusted for age, sex, and energy intake

\*, \*\*, \*\*\*; significant by Pearson's partial correlation analysis; p(0.05, p(0.01 and p(0.001, respectively

# Correlation between dietary intakes and anthropometric and hematological variables according to adiponectin genotype

Pearson's partial correlation analysis was conducted to examine the association between macronutrient intakes and anthropometric and hematological variables according to adiponectin genotype(Table 5). In G/G genotype, significant negative correlation was shown between protein intake and body weight, BMI, waist circumference, body fat mass, abdominal fat thickness, TNF-a, and leptin. Carbohydrate intake was positively correlated to concentrations of insulin and leptin. In G/T genotype, there was positive correlation between carbohydrate intake and values of BMI, body fat mass, LDL-cholesterol, and ApoB/apoA-1 ratio, and there was negative correlation between carbohydrate intake and levels of HDL-cholesterol and adiponectin. Higher protein intake was also correlated to lower ApoB/apoA-1 ratio, CRP, and leptin in G/T genotype. However, in T/T genotype, there was no significant association between macronutrients intakes and anthropometric and hematological values (p < 0.05).

## Discussion

Adiponectin SNP 276G $\rightarrow$ T has been reported to be associated with serum adiponectin concentration, insulin resistance, and CVD risk (Jang *et al.*, 2005; Qi *et al.*, 2006). In the present study, the association of SNP 276G $\rightarrow$ T at adiponectin gene with CVD risk factors in Korean type 2 DM patients was studied. The prevalence of G/G, G/T, and T/T genotype in our subjects were 47.6%, 43.3%, and 9.1%, respectively.

There have been several reports on the distributions of adiponectin gene genotypes among various populations. The prevalence of G/G, G/T, and T/T genotype were 50%, 41,7%, 8.3% in Korean non-diabetic subjects (Jang *et al.*, 200), 58.3%, 37.0%, 4.7% in Japanese type 2 DM patients (Hara *et al.*, 2002), 54.7%, 37.7%, 7.6% in American type 2 DM patients (Qi *et al.*, 2006), 50.4%, 37.6%, 12% in Italian type 2 DM patients (Bacci *et al.*, 2004), and 56%, 35.2%, 8.8% in French type 2 DM patients (Vasseur *et al.*, 2002), respectively. The prevalence of G/G genotype in our subjects was lower and of G/T genotype was higher than Japanese, American and European type 2 DM patients, and the prevalence of T/T genotype in our subjects was slightly higher than Korean non-diabetic subjects from Jang's study.

The male subjects with T/T genotype showed significantly lower adiponectin and HDL-cholesterol levels and higher CRP level compared to other two genotypes. These results suggest that the homozygotes of +276T may be associated with increased CVD risk in Korean type 2 DM patients. When the subjects were divided into high and low subgroups based on the median values of BMI, fasting blood glucose, triglyceride, and TNF-a, the association of T/T genotype with decreased serum adiponectin level was observed only in the subgroup with higher values (risk groups), not in subgroups with lower values. These results represent that the association between adiponectin genotype and serum adiponectin level may be stronger in the subjects with high CVD risk.

The association between adiponectin SNP +276 and serum adiponectin level, insulin resistance, and CVD risk is controversial. Filippi *et al.* (2005) reported that adiponectin SNP 276G→T was associated with significantly higher insulin resistance and CVD risk in Italian type 2 DM patients, and in French (Vasseur et al., 2002) and Swiss non-diabetic subjects (Menzaghi et al., 2002) adiponectin SNP 276G→T was associated with decreased concentration of serum adiponectin. On the contrary, Lacquemant et al. (2004) reported that adiponectin SNP +276 was not associated with CVD in French and Caucasian type 2 DM patients. Lee et al. (2003) presented that adiponectin SNP +276 did not have effect on insulin resistance and serum adiponectin concentration. However, in Japanese type 2 DM patients, T/T genotype showed low insulin resistance, and the serum concentration of adiponectin was higher in obese subjects with T/T genotype than other two genotypes (Hara et al., 2002). In Korean non-diabetic subjects, obese subjects with T/T genotype also showed lower insulin resistance and higher level of adiponectin than other genotypes (Jang et al., 200). It is hard to draw a conclusion on the effect of adiponectin SNP +276 on serum adiponectin level, insulin resistance, and CVD risk at present time. Differences in race, gender and disease status should be taken into account.

The results of correlation analysis between macronutrient intakes and anthropometric and hematological variables were different according to adiponectin genotypes. In G/G genotype, the negative correlation between protein intake and anthropometric variables was significant. In G/T genotype, carbohydrate intake was significantly associated with obesity parameters and lipid profiles; however, protein intake was not significantly associated with them. In T/T genotype, there was no significant association between macronutrient intakes and anthropometric and hematological parameters. These results imply that different dietary management regime based on adiponectin genotype could be helpful for preventing CVD complications in Korean type 2 DM patients; however, the number of subjects in each genotype was too small to draw a clear conclusion for dietary guidelines.

There is a limitation in the current study. Mean duration of type 2 DM of subjects in this study was 8 years. Accordingly, the medical characteristics of the subjects would be affected by medication usage and practice of diet therapy, even though no significant differences were found in medication usage and type 2 DM duration among adiponectin genotypes.

In summary, CVD risk would be high in type 2 DM patients with T/T genotype and the relation of anthropometric and hematologic factors to macronutrient intakes was different among the three adiponectin genotypes. These results imply that different dietary management regime based on adiponectin genotype could be helpful for preventing CVD complications in Korean type 2 DM patients.

#### Literature cited

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagwa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T & Matsuzawa Y (1999). Paradoxical decrease of an adipose-specific: protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 257:79-83.

- Bacci S, Menzaghi C, Ercolino T, Ma X, Rauseo A, Salvemini L, Vigna C, Fanelli R, Di Mario U, Doria A & Trischitta V (2004). The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. *Diabetes Care* 27:2015-2020.
- Bionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dina C & Froguel P (2000). Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. *Am J Hum Genet* 67:1470-1480.
- Filippi E, Sentinelli F, Romeo S, Arca M, Berni A, Tiberti C, Verrienti A, Fanelli M, Fallarino M, Sorropago G & Baroni MG (2005). The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age <or=50 years). J Mol Med 83:711-719.
- Friedwald WT, Levy RI & Fredireck DS (1972). Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. *Clin Chem* 18:499-503.
- Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Tomita M, Kimura S, Ito C, Froguel P & Kadowaki T (2002). Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. *Diabetes* 51:536-540.
- Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto U, Nakamura T, Yamashita S, Hanafusa T & Matsuzawa Y (2000). Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* 20:1595-1599.
- Jang Y, Lee JH, Chae JS, Kim OY, Koh SJ, Kim JY, Cho H, Lee JE & Ordovas JM (2005). Association of the 276G→T polymorphism of the adiponectin gene with cardiovascular disease risk factors in nondiabetic Koreans. *Am J Clin Nutr* 82:760-767.
- Kadowaki T, Yamauchi T, Kubotal N, Hara K, Ueki K & Tobe K (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. *J Clin Invest* 116:1784-1792.
- Lacquemant C, Froguel P, Lobbens S, Izzo P, Dina C & Ruiz J (2004). The adiponectin gene SNP+45 is associated with coronary artery disease in type 2 (non-insulin-dependent) diabetes mellitus. *Diabet Med* 21:776-781.
- Lee YY, Lee NS, Cho YM, Moon MK, Jung HS, Park YJ, Youn BS, Lee HK, Park KS & Shin HD (2003). Genetic association of adiponectin polymorphisms with risk of type 2 diabetes mellitus. *J Kor Diabetes Assoc* 27:438-448.
- Menzaghi C, Ercolino T, Paola RD, Berg AH, Warrm JH, Scherer PE, Trischitta V & Doria A (2002). A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. *Diabetes* 51:2306-2312.

- Mutch DM, Wahli W & Williamson G (2005). Nutrigenomics and nutrigenetics: the emerging faces of nutrition. *FASEB J* 19:1602-1616
- Oh SY, kim EM, Shin MH, Lee SH, Kim JE, Lee HS, Jo JS & Kim WY (2007). Development and validation of food frequency questionnaire for adults. *The Korean Sociey of Health Promotioon Annual spring conference*.
- Ordovas JM (2006). Nutrigenetics, plasma lipids, and cardiovascular risk. J Am Diet Assoc 106:1074-1081.
- Ouchi N, Osishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Nagasawa A, Kobayashi H, Komai N, Kaibe M, Rakugi H, Ogihara T & Matsuazawa Y (2003). Association of hypoadiponectinemia with impaired vasoreactivity. *Hypertension* 42:231-

234.

- Qi L, Doria A, Manson JE, Meigs JB, Hunter D, Mantzoros Cs & Hu FB (2006). Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. *Diabetes* 55:1512-1516.
- Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, Vaxillaire M, Lepretre F, Dupont S, Hara K, Clelannoy V, Clement K, Bihain B, Kadowaki T & Froguel P (2002). Singlenucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. *Hum Mol Genet* 11:2607-2614.